DFCM
NTLA icon

Dark Forest Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Dark Forest Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44,947
Closed -$404K – 1032
2025
Q4 		$404K Buy
44,947
+34,389
+326% +$473K 0.02% 848
2025
Q3 		$182K Sell
10,558
-25,977
-71% -$320K 0.01% 1089
2025
Q2 		$343K Buy
+36,535
New +$300K 0.01% 1008
2022
Q3 		– Sell
-11
Closed -$1K – 1347
2022
Q2 		$1K Buy
+11
New +$559 ﹤0.01% 809
2022
Q1 		– Sell
-61
Closed -$7K – 1609
2021
Q4 		$7K Sell
61
-430
-88% -$53.9K ﹤0.01% 1057
2021
Q3 		$66K Buy
+491
New +$74.3K 0.02% 500

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Dark Forest Capital Management's NTLA Position: Q1 2026 in Review

Dark Forest Capital Management sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 44,947 shares — an estimated $404K sold.

Dark Forest Capital Management first reported a position in NTLA in Q3 2021 and held it in 6 quarters. The position peaked at $404K in Q4 2025. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Dark Forest Capital Management reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Dark Forest Capital Management sold 44,947 Intellia Therapeutics shares in Q1 2026, an estimated $404K.
  • Dark Forest Capital Management first reported a position in Intellia Therapeutics in Q3 2021 and held it in 6 quarters.
  • Dark Forest Capital Management's Intellia Therapeutics position peaked at $404K in Q4 2025.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Dark Forest Capital Management's 13F filing for Q1 2026, filed 15 May 2026.